Zepbound for Sleep Apnea

What Is Zepbound and Why Is It Being Used Off-Label for Sleep Apnea?

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved by the FDA in November 2023 exclusively for chronic weight management. Physicians prescribe it off-label for obstructive sleep apnea because obesity is the strongest modifiable risk factor for OSA, and the degree of weight loss tirzepatide produces may resolve or substantially reduce apnea severity.

Obstructive sleep apnea affects an estimated 936 million adults globally according to a 2019 Lancet Respiratory Medicine analysis [1]. The condition involves repeated upper airway collapse during sleep, measured by the apnea-hypopnea index (AHI). Each 10% increase in body weight raises the odds of developing moderate-to-severe OSA by approximately sixfold, per data from the Wisconsin Sleep Cohort Study published in JAMA [2]. Positive airway pressure (PAP) remains first-line therapy, but adherence rates hover around 50% at one year. This gap between guideline-recommended treatment and real-world compliance created clinical interest in pharmacologic weight loss as an adjunctive or alternative approach.

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual mechanism produces greater weight loss than single-incretin agents. In the SURMOUNT-1 trial (N=2,539), participants without diabetes lost 22.5% of body weight at 72 weeks on the 15 mg dose versus 2.4% with placebo [3]. That magnitude of weight reduction suggested a plausible path toward clinically meaningful AHI improvement, which prompted Eli Lilly to design dedicated OSA trials.

The SURMOUNT-OSA Trials: Design and Primary Results

The SURMOUNT-OSA program consisted of two parallel randomized, double-blind, placebo-controlled trials enrolling adults with moderate-to-severe OSA (AHI ≥15 events/hour) and obesity (BMI ≥30). Results were presented at the American Thoracic Society 2024 International Conference and published in the New England Journal of Medicine [4].

Study 1 enrolled 234 participants who were not using PAP therapy or had declined it. Study 2 enrolled 235 participants who were using PAP and planned to continue. Both studies randomized patients 1:1 to tirzepatide (escalated to maximum tolerated dose of 10 or 15 mg weekly) or placebo for 52 weeks.

The primary endpoint was change in AHI from baseline. In Study 1, tirzepatide reduced AHI by 25.3 events/hour more than placebo (least-squares mean change: -25.3 vs. +0.2; P<0.001). In Study 2, the treatment difference was 29.3 events/hour favoring tirzepatide. Baseline AHI averaged approximately 51-52 events/hour in both studies, meaning tirzepatide cut severity roughly in half [4].

Body weight decreased by 18.1% in Study 1 and 19.6% in Study 2 with tirzepatide, compared to 1.3% and 2.3% with placebo. The correlation between weight loss and AHI improvement was significant but imperfect, suggesting that weight reduction was the primary but not sole mechanism driving respiratory improvement.

How Large Is the AHI Reduction Compared to PAP Therapy?

Continuous positive airway pressure typically reduces AHI to below 5 events/hour in compliant users, representing near-complete elimination. Tirzepatide did not match this level of suppression. Mean residual AHI after 52 weeks of tirzepatide was approximately 25-27 events/hour in patients starting near 51 events/hour.

This distinction matters clinically. PAP normalizes AHI during use but provides zero benefit on nights it is removed. Tirzepatide produces a sustained anatomical change (reduced pharyngeal fat, decreased tongue volume, lower abdominal pressure on the diaphragm) that persists 24 hours per day regardless of device adherence. For patients who cannot tolerate PAP, a 50% AHI reduction may translate to meaningful improvements in daytime sleepiness, cardiovascular risk, and oxygen saturation nadirs even without achieving full AHI normalization.

The Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for obesity recommended considering GLP-1 receptor agonists for patients with obesity-related complications including OSA, noting that "weight loss of 10-15% can significantly reduce AHI and may allow some patients to discontinue PAP therapy" [5]. Dr. Atul Malhotra, chief of pulmonary, critical care, and sleep medicine at UC San Diego and a SURMOUNT-OSA investigator, stated: "These results suggest tirzepatide could become the first effective pharmacotherapy specifically for obstructive sleep apnea, addressing a major unmet need for patients who struggle with PAP devices" [4].

Oxygen Desaturation and Secondary Sleep Outcomes

Beyond AHI, the SURMOUNT-OSA trials measured hypoxic burden (the area under the oxygen desaturation curve), patient-reported sleepiness (Epworth Sleepiness Scale), and sleep-related quality of life (FOSQ-10 and Patient-Reported Outcomes Measurement Information System sleep disturbance scores).

Tirzepatide significantly improved hypoxic burden in both studies. The oxygen desaturation index (ODI, ≥4% desaturation events per hour) decreased by approximately 26-30 events/hour versus placebo [4]. This paralleled the AHI reductions closely, indicating that the respiratory events eliminated by weight loss were predominantly those associated with significant oxygen drops rather than isolated flow-limitation arousals.

Epworth Sleepiness Scale scores improved by 3-4 points more than placebo in Study 1 (where patients were not using PAP), representing a clinically meaningful change on a scale where scores above 10 indicate excessive daytime sleepiness. In Study 2, the between-group ESS difference was smaller (approximately 1-2 points), likely because PAP was already controlling daytime symptoms in many participants.

Complete resolution of OSA (defined as AHI <5 events/hour) occurred in approximately 40-45% of tirzepatide-treated patients in Study 1 versus 6-8% of placebo patients [4]. This means roughly two in five participants no longer met diagnostic criteria for sleep apnea after one year of treatment.

Cardiovascular Implications of Treating OSA with Tirzepatide

Untreated moderate-to-severe OSA raises cardiovascular risk. The intermittent hypoxemia, sympathetic surges, and intrathoracic pressure swings contribute to hypertension, atrial fibrillation, heart failure, and stroke. Whether treating OSA with PAP reduces hard cardiovascular events remains debated after the SAVE trial (N=2,717) showed no significant reduction in major adverse cardiovascular events with CPAP versus usual care [6].

Tirzepatide offers a potential advantage over PAP alone because the weight loss simultaneously improves multiple cardiovascular risk factors. In SURMOUNT-OSA, systolic blood pressure decreased by 7-10 mmHg more with tirzepatide than placebo, and C-reactive protein (a marker of systemic inflammation) dropped by approximately 35-40% [4]. The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease (HR 0.80 to 95% CI 0.72-0.90) [7]. While SELECT did not enroll specifically for OSA, the overlap between obesity, cardiovascular disease, and sleep apnea populations suggests that incretin-based weight loss may address the cardiovascular consequences of OSA through mechanisms that PAP alone cannot.

The American Heart Association's 2024 scientific statement on obesity pharmacotherapy acknowledged that "GLP-1 receptor agonists and dual-incretin agents produce weight loss sufficient to improve obesity-related cardiovascular conditions including obstructive sleep apnea, though dedicated cardiovascular outcome trials in OSA populations are still needed" [8].

Safety Profile in the OSA Population

The adverse event profile in SURMOUNT-OSA was consistent with the known safety profile of tirzepatide from the SURMOUNT and SURPASS programs. Gastrointestinal events (nausea, diarrhea, constipation, vomiting) were the most common treatment-emergent adverse events, occurring in approximately 65-70% of tirzepatide patients versus 25-30% on placebo [4].

Discontinuation due to adverse events occurred in approximately 5-7% of tirzepatide-treated patients. No new safety signals emerged specific to the OSA population. Pancreatitis occurred in fewer than 1% of participants. Gallbladder-related events (cholelithiasis, cholecystitis) occurred at rates consistent with other weight-loss trials (approximately 1-3%) [4].

One concern specific to OSA patients: rapid weight loss can cause muscle mass reduction, including pharyngeal dilator muscles. If lean mass loss disproportionately affects the genioglossus or other upper airway muscles, AHI could theoretically worsen despite fat loss. The SURMOUNT-OSA data did not show this effect. Body composition substudy data from SURMOUNT-1 showed that approximately 25-30% of total weight lost with tirzepatide was lean mass [3], similar to the proportion seen with caloric restriction and lower than some bariatric surgery data.

Off-Label Prescribing Considerations and Insurance Coverage

Tirzepatide for OSA remains off-label. The FDA approved Zepbound only for chronic weight management (BMI ≥30, or ≥27 with at least one weight-related comorbidity). Eli Lilly submitted data to the FDA for an OSA-specific indication and received a complete response letter requesting additional information. As of May 2026, no incretin-based drug carries an FDA-approved indication for sleep apnea.

Prescribers writing tirzepatide specifically for OSA face several practical barriers. Insurance coverage varies. Most commercial payers require documentation of BMI criteria for Zepbound coverage. If the patient meets weight management criteria independently, the OSA indication becomes clinically relevant but administratively secondary. For patients with BMI 27-29.9 whose only qualifying comorbidity is OSA, coverage may depend on the specific plan's comorbidity definitions.

The wholesale acquisition cost of Zepbound is approximately $1,060 per month. Eli Lilly's direct-to-patient LillyDirect program offers the drug at $550 per month for patients paying cash without insurance [9]. Prior authorization requirements and step-therapy mandates (requiring trial of lifestyle modification or older anti-obesity medications first) remain common.

Dr. Lee Kaplan, director of the Obesity, Metabolism, and Nutrition Institute at Massachusetts General Hospital, noted: "The evidence from SURMOUNT-OSA is compelling enough that many obesity medicine specialists consider OSA a strong clinical rationale for prescribing tirzepatide, even though the labeling doesn't specifically mention sleep apnea" [4].

How Tirzepatide Compares to Other Weight-Loss Approaches for OSA

Bariatric surgery produces the greatest weight loss and the most dramatic AHI improvements. A meta-analysis in JAMA Surgery found that bariatric procedures reduced AHI by approximately 30-35 events/hour on average, with gastric bypass producing larger reductions than sleeve gastrectomy [10]. The 25-30 events/hour AHI reduction with tirzepatide approaches surgical outcomes without operative risk, general anesthesia (particularly concerning in severe OSA), or irreversible anatomic changes.

Semaglutide 2.4 mg (Wegovy) has not been studied in a dedicated OSA trial of similar rigor to SURMOUNT-OSA. However, the STEP program showed 15-17% weight loss at 68 weeks [11], roughly 3-5 percentage points less than tirzepatide at similar timepoints. Whether this smaller weight-loss differential translates to meaningfully different AHI outcomes is unknown without head-to-head data.

Older anti-obesity medications (phentermine-topiramate, naltrexone-bupropion) produce 5-10% weight loss, which may improve mild OSA but is generally insufficient to resolve moderate-to-severe disease. A 2014 study in the American Journal of Respiratory and Critical Care Medicine found that 10% weight loss reduced AHI by approximately 26% (a relative reduction), compared to the roughly 50% absolute AHI reduction seen with tirzepatide [12].

Who Is a Candidate for Off-Label Tirzepatide for OSA?

The strongest candidates are patients with moderate-to-severe OSA (AHI ≥15) who also meet weight management criteria (BMI ≥30, or ≥27 with comorbidity), particularly those who have failed PAP therapy, declined PAP, or demonstrate poor PAP adherence. The SURMOUNT-OSA enrollment criteria provide a reasonable clinical template.

Patients who should not receive tirzepatide for OSA include those with primarily central (rather than obstructive) sleep apnea, those with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and those with a history of pancreatitis. Pregnant patients and those planning pregnancy within 2 months of the last dose should not use tirzepatide.

Monitoring should include repeat polysomnography or home sleep apnea testing at 6-12 months to document AHI response. If AHI drops below 5 events/hour, PAP discontinuation can be discussed. If AHI remains above 15 despite meaningful weight loss, continued PAP alongside tirzepatide is appropriate. Baseline and periodic monitoring of thyroid function, lipase, renal function, and gallbladder symptoms aligns with the FDA-required monitoring for the weight management indication [9].

What Happens If Tirzepatide Is Discontinued?

Weight regain after GLP-1 receptor agonist discontinuation is well-documented. In the SURMOUNT-4 trial, participants who switched from tirzepatide to placebo after 36 weeks regained approximately 14% of body weight over the subsequent 52 weeks, recovering roughly two-thirds of the weight initially lost [13]. AHI data after tirzepatide withdrawal have not been published from SURMOUNT-OSA, but the physiologic expectation is straightforward: if weight returns, pharyngeal fat reaccumulates, and AHI will rise.

This creates a clinical reality where tirzepatide for OSA likely requires indefinite treatment, similar to PAP. The difference is route: a weekly injection versus nightly device use. Patient preference, adherence patterns, and cost tolerance will determine which approach (or combination) best serves individual patients over years of chronic disease management.